DescriptionSources: Marieb E (2014). Anatomy & physiology. Glenview, IL: Pearson Education, Inc. ISBN 978-0-321-86158-0.Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26512
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf
Sources: Marieb E (2014). Anatomy & physiology. Glenview, IL: Pearson Education, Inc. ISBN 978-0-321-86158-0.
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26512
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf
Argipressin is a neurohypophysial hormone from the vasopressin hormone family. Its two primary functions are to retain water in the body and to constrict blood vessels. The antidiuretic action of Argipressin is ascribed to increase in reabsorption of water by the renal tubules. Argipressin can cause contraction of smooth muscle of the gastrointestinal tract, gall bladder, urinary bladder and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. Agripressin for injections is used for use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. In addition, argipressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
CNS Activity
Curator's Comment: As a neurotransmitter and/or neuromodulator VP can modulate CNS autonomic systems controlling heart rate, arterial blood pressure, respiration rate, and sleep patterns, however, physiological significance is not understood. VP may also have an effect on certain learned behaviors, in the development of some complex social problems, and in the pathogenesis of complex psychiatric diseases such as depression.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P37288 Gene ID: 552.0 Gene Symbol: AVPR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
0.24 nM [EC50] | ||
Target ID: P47901 Gene ID: 553.0 Gene Symbol: AVPR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
0.05 nM [EC50] | ||
Target ID: P30518 Gene ID: 554.0 Gene Symbol: AVPR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787 |
4.3 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Argipressin 20 IU/ml Solution for Injection Approved UseFor use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. |
|||
Primary | Argipressin 20 IU/ml Solution for Injection Approved UseFor use in diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices. |
|||
Primary | VASOSTRICT Approved UseTo increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. Launch Date2014 |
|||
Palliative | PITRESSIN Approved UseVasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus |
|||
Diagnostic | PITRESSIN Approved UseVasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. |
PubMed
Title | Date | PubMed |
---|---|---|
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. | 1995 May 15 |
|
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. | 1998 Dec |
|
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. | 1999 Oct |
|
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. | 2000 Apr |
|
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. | 2000 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/26512
For treatment of diabetes insipidus: A dose of 0.25ml to 1ml (5 to 20 units) by subcutaneous or intramuscular injection every four hours. For the initial control of variceal bleeding Argipressin should be given intravenously. Argipressin, 20 units diluted in 100ml dextrose 5% w/v may be infused over a 15 minute period.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21688787
Agonist activity of compound at the human vasopressin V1aR was determined in a reporter gene assays (RGA) in HEK293 cells by transiently cotransfecting recombinant vasopressin V1aR expression vectors and the reporter plasmid containing a luciferase gene under the control of NFAT response elements (NFAT-luciferase). Argipressin activates V1aR with EC50 of 0.24 nM.
Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 18:20:20 GMT 2025
by
admin
on
Mon Mar 31 18:20:20 GMT 2025
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
Y4907O6MFD
|
Record Status |
FAILED
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
26928-2
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
LOINC |
3126-0
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
WHO-ATC |
H01BA01
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
LOINC |
14949-2
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
WHO-ATC |
H01BA06
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
NCI_THESAURUS |
C80212
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
WHO-VATC |
QH01BA06
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
||
|
LOINC |
13903-0
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C926
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
Y4907O6MFD
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
m11399
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
9937
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
644077
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
DTXSID0048349
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
Vasopressin
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108986
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
9937
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
204-035-4
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
2168
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
Y4907O6MFD
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
SUB05082MIG
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
34543
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
113-79-1
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
1098
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
ALTERNATIVE | RxNorm | ||
|
CHEMBL373742
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
1482
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
34543
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
1711100
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
11149
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
DBSALT002464
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
DB00067
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
SUB20776
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
2810
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
D001127
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
SUB05561MIG
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY | |||
|
100000086520
Created by
admin on Mon Mar 31 18:20:20 GMT 2025 , Edited by admin on Mon Mar 31 18:20:20 GMT 2025
|
PRIMARY |
From | To |
---|---|
1_1 | 1_6 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
LABELED -> NON-LABELED |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
AMINO_ACID_SUBSTITUTION | [1_9] | C-TERMINUS | GLYCINE |
Amount:
|
GLYCINAMIDE | 4JDT453NWO |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|